SCHEDULE: Stonepine Capital Discloses 6.9% Stake in Edesa Biotech

Stonepine Capital Management, LLC and its affiliates have reported beneficial ownership of 6.9% of Edesa Biotech, Inc.'s common shares, including shares and warrants.

Summary

• Stonepine Capital Management, LLC, along with Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico, have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 953,739 shares of Edesa Biotech, Inc. common stock.
• This represents 6.9% of the total outstanding common shares.
• The reported holdings include 703,739 shares of Common Shares and warrants to acquire 250,000 shares of Common Stock.
• The beneficial ownership is subject to a 9.99% limitation for the warrants.
• The percentage is calculated based on 13,503,723 shares outstanding as of August 20, 2026, following an offering.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake by an investment firm. The focus is on disclosure rather than company performance.

Positives

• Significant investment by Stonepine Capital, indicating confidence in Edesa Biotech's potential.
• The filing clearly discloses the ownership stake, providing transparency to the market.
• The investment includes both common shares and warrants, suggesting a long-term perspective.

Negatives

• The filing does not provide any financial performance data or operational updates for Edesa Biotech.
• The primary purpose is disclosure of ownership, not an assessment of company health.

Risks

• The beneficial ownership is subject to a 9.99% limitation on warrants, which could affect future share acquisition.
• The filing does not detail the specific strategy or investment thesis behind this stake.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Edesa Biotech's future performance. It solely reports on ownership stakes.

Management Comments

• Each reporting person disclaims membership in a group and beneficial ownership except to the extent of their pecuniary interest.
• The filing of the Schedule 13G by the Partnership should not be construed as an admission that it is a beneficial owner of any shares covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing indicates Stonepine Capital's strategic interest in Edesa Biotech within the biotechnology sector, a field often characterized by substantial investment and potential for growth or volatility.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake, which could influence market perception.
• Management of Edesa Biotech: Awareness of a substantial shareholder's interest and potential influence.
• Potential Investors: Information that may inform investment decisions regarding Edesa Biotech.

Next Steps

• Continued monitoring of Edesa Biotech's performance and any further filings by Stonepine Capital.
• Potential for Stonepine Capital to increase or decrease its stake in Edesa Biotech.

Key Dates

Keywords

Edesa Biotech, Stonepine Capital, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Investment Management